Floatz logo

Olverembatinib

Acute Lymphoblastic Leukemia, Adult

Institute of Hematology & Blood Diseases Hospital, ChinaSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

73 Active assets in the Acute Lymphoblastic Leukemia, Adult cohort.

Asset / SponsorPhaseRating
MERCAPTOPURINE ANHYDROUS
Shanxi Bethune Hospital
Phase 4A
DEXAMETHASONE
Shanxi Bethune Hospital
Phase 4BBB
METHOTREXATE
PETHEMA Foundation
Phase 4BBB
Cyclophosphamide
The First Affiliated Hospital of Zhengzhou University
Phase 4BBB
Cytosin-Arabinosid
PETHEMA Foundation
Phase 4BBB

View all 50 →

Same molecule, other indications

Olverembatinib is also rated in:

B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
66 / 100
View asset →
childhood acute lymphoblastic leukemiaDormant
BB
Indicative ·
64 / 100
View asset →
precursor B-cell acute lymphoblastic leukemiaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →